The MHC class-II HLA-DR receptor mediates bat influenza A-like H17N10 virus entry into mammalian cells

Efstathios S Giotis^{1*}, George Carnell^{2,3}, Erik F. Young^{4†}, Saleena Ghanny^{4††}, Patricia Soteropoulos^{4††}, Wendy S Barclay¹, Michael A Skinner¹, Nigel Temperton²

¹Section of Virology, Department of Medicine, St Mary's Campus, Imperial College London, UK.

²Viral Pseudotype Unit, Medway School of Pharmacy, University of Kent and University of Greenwich, Chatham Maritime, UK.

³Laboratory of Viral Zoonotics, Department of Veterinary Medicine, University of Cambridge, UK.

⁴Hackensack University Medical Centre Department of Surgery, Hackensack, NJ.

Current affiliations:

[†]Bioelectronic Systems Lab, Columbia University, NY, USA.

^{††}University of Medicine and Dentistry of New Jersey, Centre for Applied Genomics, Newark, NJ, USA.

*Corresponding author: Efstathios S Giotis e.giotis@imperial.ac.uk

Abstract:

Bats are notorious reservoirs of diverse, potentially zoonotic viruses, exemplified by the evolutionarily distinct, influenza A-like viruses H17N10 and H18N11 (BatIVs). The surface glycoproteins [haemagglutinin (H) and neuraminidase (N)] of BatIVs neither bind nor cleave sialic acid receptors, which suggests that these viruses employ cell attachment and entry mechanisms that differ from those of classical influenza A viruses (IAVs). Identifying the cellular factors that mediate entry and determine susceptibility to infection will help assess the host range of BatIVs. Here, we investigated a range of cell lines from different species for

their susceptibility to infection by pseudotyped viruses (PV) bearing bat H17 and/or N10 envelope glycoproteins. We show that a number of human haematopoietic cancer cell lines and the canine kidney MDCK II (but not MDCK I) cells are susceptible to H17-pseudotypes (H17-PV). We observed with microarrays and qRT-PCR that the dog leukocyte antigen DLA-DRA mRNA is over expressed in late passaged parental MDCK and commercial MDCK II cells, compared to early passaged parental MDCK and MDCK I cells, respectively. The human orthologue HLA-DRA encodes the alpha subunit of the MHC class II HLA-DR antigen-binding heterodimer. Small interfering RNA- or neutralizing antibody-targeting HLA-DRA, drastically reduced the susceptibility of Raji B cells to H17-PV. Conversely, over expression of HLA-DRA and its paralogue HLA-DRB1 on the surface of the unsusceptible HEK293T/17 cells conferred susceptibility to H17-PV. The identification of HLA-DR as an H17N10 entry mediator will contribute to a better understanding of the tropism of the virus and will elucidate its zoonotic transmission.

Keywords: influenza, bats, pseudotype virus, MHC-class II, HLA-DR

Abbreviations: SARS: severe acute respiratory syndrome; MERS: Middle-East respiratory syndrome; CoV: coronavirus; MDCK: Madin-Darby canine kidney cells; HIV: human immunodeficiency virus; CD4: cluster of differentiation 4; MHC: Major histocompatibility complex; ATCC: American type culture collection; gag: group-specific antigen; pol: polymerase; SEM: standard error of the mean.

Main:

Outbreaks of SARS, MERS, Nipah and Ebola have highlighted the critical need to focus on the zoonotic potential of known, and novel, bat viruses to improve forecasting, prevention and control of epidemics. Viral diversity in bats is exemplified by the discovery of the enigmatic

influenza A-like viruses (BatIVs) H17N10 and H18N11 in asymptomatic New World bats (*Sturnira lilium* and *Artibeus planirostris* respectively)^{1,2} and more recently by the detection of a virus related to avian H9N2 in Egyptian *Rousettus aegyptiacus* bats³. Such discoveries prompted investigation of the pandemic potential of these viruses and led to concern that bats may be a neglected reservoir of novel influenza viruses⁴.

Influenza A viruses (IAVs) are enveloped orthomyxoviruses with eight single-stranded negative-sense viral RNAs (vRNAs) encapsidated into viral ribonucleoproteins (vRNPs). The original source of classical IAVs is aquatic birds, from which they emerge, *via* genome reassortment and mutation, to cause sporadic pandemics in humans, lower animals and other birds^{5, 6}. They are classified into different subtypes based on their envelope glycoproteins (trimeric haemagglutinin, HA: H1-H18, and tetrameric neuraminidase, NA: N1-N11)⁷. HA is synthesised as a precursor protein in infected cells and its cleavage by host cell proteases sets in motion a complex series of events that is initiated by receptor binding and is terminated with the penetration of the virus into the cytoplasm of target cells⁸. HA conventionally attaches to host-specific sialic acid (SA) moieties⁶. These are terminal sugars of larger carbohydrate chains attached to the cell membrane by the lipids or proteins that they decorate. When HA attaches to them, it triggers endocytosis of the virus into membrane bound endosomes^{9, 10}. Acidification of the endosome induces conformational changes to HA, which lead sequentially to: insertion of the hydrophobic “HA fusion peptide” into the host membrane, juxtaposition of the viral and endosomal membranes and subsequent release of the vRNPs into the cytoplasm via a fusion pore^{11, 12}. In contrast, NAs are glycosidases which primarily cleave cell surface SA and therefore facilitate the release and spread of virus progeny upon egress, as well as disaggregation of virions before entry^{13, 14}.

The crystal structures of BatIV HAs and NAs revealed divergence of their protein conformations from those of conventional IAVs, suggesting distinct binding and functional properties^{2, 15, 16, 17}. Bat H17 and H18 proteins have typical HA folds but lack an obvious cavity

to accommodate SA^{2, 15, 17}. The cell receptors for the BatIVs are as yet unidentified, but they are clearly not SA moieties, a conclusion reached by several studies^{15, 18, 19}. Furthermore, bat N10 and N11 are structurally similar to classical NAs but lack conserved amino acids for SA binding and cleavage^{2, 16, 17} and do not exhibit typical neuraminidase activity^{18, 20}. Initial efforts to isolate infectious BatIVs directly from bats have failed, mainly because the receptors were unknown and susceptible cell lines were unavailable^{21, 22, 23}. Attempts to circumvent these limitations have included H17- or H18-pseudotyped vesicular stomatitis virus (VSV^{19, 24}), engineered BatIV/IAV chimeric viruses^{23, 25}, and authentic BatIVs reconstructed using reverse genetics²⁶. H17-VSV was able to infect bat cell lines (EidNi, HypNi, and EpoNi) but only a few, common cell lines of flightless mammals, including some of human (U-87 MG glioblastoma and SK-Mel-28 melanoma) and canine (RIE1495 and MDCK II kidney) origin^{19, 24, 26}. These cells could also be infected with reconstructed H17N10 and H18N11 viruses²⁶. The ability of BatIVs to infect mammalian cell lines *in vitro*, and their unconventional features, raised concerns about their zoonotic and epidemic potential. Identifying the BatIV cell surface receptors and delineating the mechanistic basis of the host-virus interaction are key to assessing their potential host range and public health significance.

HIV-1 derived-pseudotypes bearing heterologous envelope proteins (PV) have been used widely for the assessment of cellular tropism and the identification of cellular receptors or attachment factors for a range of viruses^{27, 28, 29, 30, 31}. Such pseudotypes have proved a reliable model to study the capacity of H17N10 for entry into various cell lines^{27, 32}. Using this approach, we have shown that H17-PV, and H17N10-PV (A/little yellow-shouldered bat/Guatemala/060/2011) are recovered from producer HEK293T/17 cells exclusively in the presence of the human airway trypsin-like protease (HAT) or the transmembrane protease, serine 2 (TMPRSS2) (Fig. 1a)³². In this study, a panel ($n=35$; Supplementary material 1) of cell lines from different tissues and species were challenged with H17- and/or N10-PV to study

the distribution of the H17N10 receptor(s) (Fig. 1b). Efficiency of infections with PV was quantified (after 48 h) by the expression of a firefly luciferase (FLuc) reporter gene encoded by the lentiviral genome. Parallel infections were conducted with PV bearing either classical H5 (H5-PV; A/Vietnam/1194/2004; H5N1 clade 1) or VSV-G (VSV-G-PV) glycoproteins (the latter displaying very broad tropism) as positive controls to eliminate possible post-binding blockage factors. HIV particles produced in the absence of a viral envelope protein (Δ -env) served as a negative control. H17-PV displayed highly limited host and species cell tropism, suggesting that the H17 cellular receptor(s) are not ubiquitous (Fig. 1b). Of note, the bat cell lines (lung & kidney) from *S. lilium* in which H17N10 was discovered, were not susceptible to PV. This implies that expression of the H17-putative receptor(s) and/or viral entry-related host factors was either lost during immortalisation or is tissue-type restricted. Conversely, we show that the dog epithelial kidney MDCK II (unlike MDCK I) cells are susceptible to H17-PV with titers comparable to those of control VSV-G- and H5-PV in the range of 10^6 to 10^7 RLU/ml (Fig. 1c). They were not susceptible to PV expressing N10 alone and co-expression of N10 with H17 did not improve infection of MDCK II (Fig. 1c), which suggests that N10 has a dispensable role in viral entry (*in vitro*). To characterise the H17 putative receptors, MDCK II cells were either pre-treated with neuraminidase, tunicamycin or pronase or treated with ammonium chloride before infection with H17-PV. Infectivity with H17- and H5-PVs, as well as cytotoxicity (by trypan blue exclusion), were assayed 24 h post treatment (Fig. 1d). Pre-treatment of MDCK II cells with neuraminidase from *Clostridium perfringens* (1-100 mU), which cleaves cell surface SA, reduced H5-PV infection by 68-86% but did not significantly affect infection by H17-PV, supporting the notion that SA are not the cell surface receptors for H17^{19, 26}. Classical IAVs primarily enter cells via endocytosis followed by endosomal fusion triggered by low pH. Treatment of MDCK II cells with the pH neutralising agent ammonium chloride (1-100 mM) abolished luciferase activity for both H5- and H17-PV, demonstrating that entry of H17, like IAVs, into target cells is pH-dependent. Similar results were obtained in

131 RIE1495 cells³². Entry of H17-PV was more susceptible to pre-treatment of MDCK II cells with
 132 proteases or tunicamycin (an inhibitor of *N*-glycosylation) than was entry of H5-PV (being
 133 reduced by up to 72 and 78%, compared to 45 and 20%, respectively), suggesting that the
 134 H17-cellular receptor(s) may be a glycosylated protein, in line with previous proposals¹⁹.

135

136 MDCK I and II represent early and late passaged cells from the same parental NBL-2 cell line
 137 (CCL-34, ATCC). MDCK are valuable cell lines in studies of viruses, cell-cell junctions and
 138 epithelial differentiation but consist of heterogeneous cell populations and their phenotypes
 139 vary significantly between user laboratories³³. In addressing the factors that permit infection
 140 of H17-PV in late passaged MDCK II cells, we considered that parental NBL-2 cells undergo
 141 passage number-dependent phenotypic changes that may be reflected at transcriptional level.
 142 The phenotypic transition of NBL-2 cells to early and late MDCK cells was investigated using
 143 the Affymetrix canine microarray 2.0 (E-GEOD-14837; passages 8 and 21 respectively). The
 144 microarray analysis identified 17 differentially regulated transcripts: 12 up-regulated and 5
 145 down-regulated in late- compared to early-passaged cells (Fig. 2a). The current prevalent
 146 hypothesis is that single or multiple cell surface molecules are essential for the initial
 147 attachment and uptake of enveloped viruses into cells^{34, 35}. Therefore, we surveyed the
 148 differentially regulated transcripts for encoded, surface-anchored proteins using a combined
 149 analysis of: available Gene Ontology annotations, existing literature as well as transmembrane
 150 protein domain and subcellular localisation prediction algorithms (Phobius, TMHMM and
 151 DeepLoc). The analysis identified the dog leukocyte antigen class II DR α -chain (DLA-DRA) as
 152 the only transcript, encoding a membrane protein, over-expressed in late, compared to early,
 153 passage MDCK cells (full data in Supplementary material 2). Significant over-expression of
 154 DLA-DRA (and its paralogue DLA-DRB1) was also confirmed (by qRT-PCR) in MDCK II
 155 compared to MDCK I cells (Fig. 2b).

156

DLA-DRA is a well-conserved orthologue of the human leukocyte antigen class II DR α -chain (HLA-DRA) (~90% amino acid identity between canine, human and *Desmodus rotundus* bat ectodomains; Supplementary material 3). In humans, MHC-II molecules occur as three highly polymorphic isotypes (HLA-DR, HLA-DP and HLA-DQ) which are selectively expressed under normal conditions on the surface of antigen presenting cells (APCs), including B, dendritic and mononuclear phagocyte cells. These molecules are non-covalently associated heterodimers of two glycosylated, transmembrane polypeptide chains, the monomorphic 35-kDa α -chain and the highly polymorphic 28-kDa β -chain³⁶. Both chains have an extracellular portion composed of two domains (α 1 and α 2, or β 1 and β 2) that is anchored on the cell membrane by short transmembrane and cytoplasmic domains (Fig. 2c). In the classical scenario, the protease-derived foreign antigen peptides bind to MHC class II proteins in the cleft formed by the α 1 and β 1 domains, and the complex is transported to the cell surface^{36, 37}. When antigenic peptides are not available, endogenous peptides such as the class II associated invariant peptide (CLIP) substitute them and restore MHC class II dimer stability³⁷. The complex of HLA-DR and endocytosed peptides (usually 9-30 amino acids in length), constitutes a ligand for the T-cell receptor (TCR) and plays a key role in the presentation of foreign antigens to CD4⁺ T helper cells and immune surveillance^{38, 39}.

Since the ultimate goal of our studies is to obtain insight on the zoonotic potential of H17N10, we focused on the possible influence of HLA-DR on cellular susceptibility to H17. Hence, taking advantage of the high expression of HLA-DR on certain human hematopoietic carcinomas⁴⁰, we further explored H17-PV tropism using a panel of human leukaemia and lymphoma cell lines (Fig. 2d). We found that the Burkitt's lymphoma-derived Raji, Ramos and BJAB B-lymphocytes and the B lymphoblastoid cells (B-LCL) show decreasing susceptibility, in that order, to H17-PV. Kasumi-1 leukaemic cells showed marginal susceptibility in terms of luciferase activity, while Molt-4 and HL-60 leukaemic cells, Jurkat T-cells, pro-monocytic THP-

183 1 and U-937 cells, and primary B cells showed no susceptibility to the pseudotypes (Fig. 2d,
 184 left Y axis). We hypothesised that the different susceptibility of the various cell types by H17-
 185 PV were due to disparate expression of HLA-DR, confirmed by qRT-PCR analysis for a non-
 186 polymorphic region of the α chain of HLA-DR on the same samples (Fig. 2d, right Y-axis). The
 187 presence of the HLA-DR heterodimer was also confirmed by flow cytometry with a FITC-
 188 conjugated monoclonal antibody (clone Tü36), which specifically binds to a monomorphic
 189 epitope on the HLA-DR α/β complex and not the isolated α or β chains (Fig. 2e)⁴¹. Both
 190 approaches indicate association between mRNA levels, the surface expression of HLA-DR
 191 heterodimer and susceptibility to H17-PV. Raji, BJAB and Ramos B cells were found to consist
 192 of 100% HLA-DR⁺ cells; Kasumi-1 demonstrated a 7% subpopulation of HLA-DR⁺ cells and
 193 MOLT-4 and HL-60 cells were 100% HLA-DR⁻. These results were relatively constant and did
 194 not change with factors such as cell density or passage number.

195

196 To confirm the influence of HLA-DR on H17-PV entry into B cells, HLA-DR was independently
 197 suppressed by siRNA-mediated inhibition or by antibody blocking. Raji B cells were
 198 transfected twice over 48 h with an siRNA mixture specific for HLA-DRA (siHLA-DRA) or a
 199 control siRNA (siControl) and then challenged with the H17-PV for another 48 h. The
 200 efficiency of HLA-DRA knock-down was confirmed by qRT-PCR and western Blot. The mRNA
 201 and protein expression of HLA-DRA was reduced by $\geq 50\%$ in Raji cells transfected with
 202 siHLA-DRA compared to those transfected with siControl. Knocking down HLA-DRA in Raji
 203 cells correspondingly reduced the infection of H17-PV by 50% (Fig. 2f).

204

205 To determine if blocking attachment of virus to the HLA-DR ectodomain can prevent its entry,
 206 Raji cells were incubated with increasing concentrations of a monoclonal antibody (mAb
 207 Clone 302CT2.3.2) targeting a monomorphic, extracellular region of the HLA-DRA antigen

(HLA-DRA epitope: amino acids 48-75). The presence of the antibody significantly reduced, in a dose-dependent manner, infection with H17-PV but not VSV-G-PV (Fig. 2g).

We next sought to ascertain whether ectopic expression of HLA-DR was sufficient to increase the susceptibility of non-APC, HEK293T/17, cells to the H17-PVs. HEK293T/17 cells were transiently transfected with the DRA expression vector, alone or in combination with DRB1. Surface expression of the α/β heterodimer was validated using immunofluorescence and flow cytometry. Expression of either DRA or DRB1 alone resulted in marginal or no increase in surface staining of HLA-DR or H17-PV infection (data not shown). In contrast, 1:1 co-expression of both DRA and DRB1 formed a functional α/β heterodimer on the cell surface in approximately 47% of the cell population (Fig. 2h and Supplementary material 4). This suggests that both α and β chains are necessary for cell-surface expression, consistent with previous studies^{42, 43}. Transient over expression of HLA-DR in HEK293T/17 cells resulted in significant infection by H17-PV. Infection was higher by more than two orders of magnitude (Fig. 2i) in Fluorescence-activated cell sorting (FACS)-sorted cells enriched for HLA-DR. Further, expression of the human HLA-DR α and β chains in the bat *Pteropus alecto* kidney PakiTO3 cells allowed infection with H17-PV (Supplementary material 5).

Taken together, HLA-DR is shown to function as a *bona fide* entry mediator for H17 but may function with unknown factors that facilitate virus internalisation. Interaction between HLA-DR and H17 may trigger viral entry through canonical receptor-mediated endocytosis, but could also trigger entry through an activation of cell signalling pathways that the virus subverts to its advantage. Our finding therefore raises questions on the utility and possible evolutionary advantage(s) that an APC-associated receptor would confer to H17N10 infectivity and broader fitness. Some viruses exploit cells of the immune system, such as macrophages, B and dendritic cells, either as viral reservoirs or as “Trojan horses” to

penetrate the epithelial barriers^{44, 45}. The measles virus for example, exploits macrophages or dendritic cells, which traffic the virus to bronchus-associated lymphoid tissue or regional lymph nodes, resulting in local amplification and subsequent systemic dissemination by viremia⁴⁶. A similar strategy employed by H17N10 could provide an explanation on why viral RNA was detected in different organs and tissues in carrier *S. lilium* bats (i.e. lung, kidney, liver, intestine) and why the virus fails to grow *in vitro* in cell lines developed from the same tissues^{1, 26}. The prototypic gammaherpesvirus, Epstein-Barr virus (EBV), employs resting B cells as transfer vehicles for infection of epithelial cells⁴⁷, and also uses the HLA-DR (β 1 domain) as receptor in order both to enter B cells as well as to impair antigen presentation (by sterically blocking the engagement of HLA-DR1 and the TCR V α domain)^{48, 49, 50}. It is possible that through efficient binding to HLA-DR, H17N10 may have developed a means of simultaneously accessing lymphoid cells and blocking T-cell responses. Such an immune evasion mechanism could explain, at least partially, its survival and asymptomatic status in carrier bats. With limited functional information available on the bat MHC-II, the biological role of the host HLA-DR orthologue in the pathogenesis and transmission mechanisms of the H17N10 virus remains obscure.

In this study we did not establish the stoichiometry of the HLA-DR: H17 engagement, or clarify how the virus moves to sub-membranous regions and might hijack the receptor-mediated signalling pathway to promote its internalization. It is likely that the determinants of viral entry *in vivo* are more complicated. We cannot rule out the use by H17N10 (as by other bat-borne viruses, *e.g.* SARS CoV^{51, 52}) of more than one molecular species as (co-) receptors. Nevertheless, the implication of this study is that H17N10 has the capacity to enter human HLA-DR⁺ cells and our work provides substantial evidence that the H17N10 virus has zoonotic potential. The current finding not only sheds light on the understanding of BatIV host range, but also provides additional information on the evolution of influenza A viruses.

260

261 **Materials and methods**

262 **Cell lines, cell culture and treatment**

263 Cell lines (complete description in Supplementary material 1) were kindly provided as
 264 follows: the HEK293T/17 cells were provided by Dr Edward Wright (University of
 265 Westminster, UK); Kasumi-1, HL-60, Molt-4, Jurkat cells from Professor Paul Farrell (Imperial
 266 College London, UK); *Pteropus alecto* cell lines from Professor Linfa Wang (NUS Duke,
 267 Singapore); *Sturnira lilium*, *Artibeus planirostris*, and *Carolia perspicillata* cell lines have been
 268 generated in the labs of Dr Carles Martínez-Romero/Professor Adolfo Garcia-Sastre (Icahn
 269 School of Medicine, New York) from bat tissue samples originally collected by Dr Eugenia
 270 Corrales-Aguilar (University of Costa Rica); B-LCL were created by Dr Konstantinos Paschos
 271 by infecting with recombinant EBV B cells from isolated peripheral blood monocytes (PBMCs)
 272 of a healthy donor of the prototypical B95-8 background (Imperial College London); Raji,
 273 Ramos and BJAB from Dr Rob White (Imperial College London); U-937 and THP-1, BEAS-2B,
 274 Caco-2 from Dr Marcus Dorner, Dr Michael Edwards and Professor Robin Shattock
 275 respectively (Imperial College London). The rest of cell lines were either from the collection of
 276 Dr Michael Skinner or from ATCC. Primary B cells were a kind gift by Dr Rob White (Imperial
 277 College London). B cells were isolated from peripheral blood leukocyte (PBL) samples
 278 obtained from anonymous buffy coat donors (UK Blood Transfusion Service) by
 279 centrifugation over Ficoll. CD19 microbeads were used for magnetic separation of purified B
 280 cells using an autoMACS separator (Miltenyi Biotec). All cell lines in this study were cultured
 281 according to standard mammalian tissue culture protocols (ATCC; www.atcc.org). Bat cell
 282 lines were propagated in Dulbecco's modified eagle medium (DMEM) (Life Technologies)
 283 supplemented with heat-inactivated 15% fetal bovine serum (Life Technologies), penicillin
 284 (100 U/ml) and streptomycin (100 µg/ml; Invitrogen). All cells were maintained in a

humidified incubator at 37°C and 5% CO₂ and were found free of mycoplasma contamination on repeated testing with the MycoFluor Mycoplasma Detection Kit (Life Technologies, UK). MDCK II cells were treated as previously¹⁹ with the following modifications. MDCK II cells were either treated with the endosomal acidification reagent ammonium chloride (1, 10 or 100 mM), or pre-treated with neuraminidase from *Clostridium perfringens* for 2 h (1, 10 or 100 mM) or pronase (a mixture of endo- and exoproteases from *Streptomyces griseus* at a final concentration of 5, 10 or 50 µg/ml; Calbiochem, UK) for 30 min, an N-glycosylation inhibitor (tunicamycin from *Streptomyces* sp. at a final concentration of 0.01, 0.1 or 1 µg/ml; Sigma-Aldrich, UK) for 5 h. Pre-treated cells were washed with phosphate buffer saline (PBS) 3 times, and then incubated/infected as before with PVs for another 24 h. Cell viabilities were assessed by a trypan blue exclusion test.

Lentiviral pseudotype virus production and susceptibility assays

Pseudotypes expressing H17 and N10 genes were produced as described previously^{32, 53}. Briefly, the lentiviral packaging plasmid p8.91⁵⁴, the pCSFLW firefly luciferase lentiviral vector⁵⁵ or the GFP expressing vector pCSGW, the expression plasmids for H17 and/or N10 [vector pl.18⁵⁶ and the protease encoding plasmid pCAGGS-HAT (a kind gift by Eva Böttcher-Friebertshäuser, Philipps University of Marburg, Germany) were co-transfected using polyethylenimine transfection reagent (Sigma Aldrich, UK) into HEK293T/17 cells, plated on 6-well Nunclon® plates (Thermo Fisher Scientific, UK). Supernatants were collected 48-72 h post transfection and filtered through a 0.45 µm filter (Millipore, UK). To remove viral titer bias between different PV stocks, pseudotypes were concentrated and (re-) titrated by serial dilution. Concentration was carried out by ultra-centrifugation for 2 h at 25,000 rpm, 4°C in the SW32 rotor of a L2-65B Beckman ultra-centrifuge. Two-fold serial dilutions of PV-containing supernatant were performed as previously described³² using white 96-well Nunclon® plates (Thermo Fisher Scientific, UK).

311 Subsequently, approximately 1×10^4 (for adherent) and 3×10^4 cells (for suspension) cells were
 312 added in 50 μ l of medium per well. Plates were incubated for 48 h, after which 50 μ l of
 313 Bright-Glo™ substrate (Promega, UK) was added. Luciferase readings were conducted with a
 314 luminometer (FLUOstar OPTIMA, BMG Labtech) after a 5-minute incubation period and
 315 luciferase reading recorded in relative luminescence units (RLU). Data were normalized using
 316 Δ -env and cell-only measurements and expressed as RLU/ml.

317 **Plasmids and transfections**

318 Mammalian expression plasmids (pcDNA3.1+/C-(K)DYK) for HLA-DRA (NM_019111) and
 319 HLA-DRB1 (NM_001243965) were purchased from GenScript (Piscataway, NJ; USA).
 320 HEK293T/17 cells at sub-confluence in 6-well plates or 100 mm dishes were transfected
 321 with HLA-DRA plasmid or HLA-DRB1 plasmid or a 1:1 combination of both using the
 322 Lipofectamine 3000 transfection reagent (Thermo Fisher Scientific, UK) according to
 323 manufacturer instructions. 48 h after transfection, cells were used either for
 324 immunofluorescence analysis, or for FACS analysis (cell-surface staining) or for infection
 325 with PV. Under the experimental conditions, the transfection efficiency in either plate/dish,
 326 as assessed by the GFP expression of a co-transfected GFP-expressing control plasmid, was
 327 >70% under microscopic observation. For HLA-DR stably over expressing cells, PakiTO3
 328 cells were transfected with both HLA-DR plasmids and then selected with neomycin (500
 329 μ g/ml). Single clones were analysed for expression of the over expressed proteins.

330 **RNA isolation for microarray analysis**

331 Total RNA was isolated from biological triplicates of early and late passage MDCK from T25
 332 flasks that had been seeded with 8×10^5 cells and allowed to become confluent and polarize
 333 over 4 days in culture cells using a Ribopure kit (Ambion, Austin, TX). Acquired RNA was
 334 precipitated with EtOH and subsequently purified employing columns, procedures and
 335 reagents from an RNEasy kit (Qiagen, Germantown, MD) and resuspended in RNase-free H₂O.
 336 Complementary DNA and RNA synthesis were performed according to Affymetrix Expression

337 Analysis protocols (see www.affymetrix.com). Briefly, double-stranded cDNA was synthesized
338 from 5 µg of total RNA using the Superscript double-stranded cDNA synthesis kit (Invitrogen).
339 Following phenol/chloroform extraction and ethanol precipitation, a biotin-labeled in-vitro
340 transcription reaction was carried out using the cDNA template (Enzo Life Sciences,
341 Farmingdale, NY). Fifteen micrograms of cRNA was fragmented for hybridization to
342 Affymetrix Canine Genome 2.0 Array GeneChips (Santa Clara, CA), which contains
343 approximately 18,000 *C. familiaris* mRNA/EST-based transcripts and over 20,000 non-
344 redundant predicted genes. An one-way ANOVA adjusted with the Benjamini–Hochberg
345 multiple-testing correction [false discovery rate (FDR) of $P < 0.05$] was performed with Partek
346 Genomics Suite (v6.6 Partek) across all samples as previously⁵⁷. Principal component analysis
347 confirmed that batch mixing had prevented introduction of experimental bias. Comparisons
348 were conducted between early and late passaged cells. The analysis cut off criteria were fold
349 change $\geq \pm 1.5$ and P -value ≤ 0.05 . Microarray data was uploaded per MIAME standards and
350 deposited at the GEO repository and is available under series record number GSE14837.

351

352 **HLA-DRA knockdown and blocking using siRNA and monoclonal antibodies**

353 A Sigma-Aldrich MISSION esiRNA endonuclease-derived mixture of siRNAs (EHU226621) was
354 used to knock down HLA-DRA expression in Raji cells. Lipofectamine RNAiMAX transfection
355 Reagent (Thermo Fisher Scientific, UK) was used to transfect exponentially grown Raji cells
356 with 50 nM of siHLA-DRA or siRNA universal negative control (Sigma-Aldrich, UK; SIC001)
357 according to the manufacturer's instructions. The transfection was repeated the following day
358 and cells were collected after 48 h and either seeded at 3×10^4 cells per well in a 96 well-plate
359 for infection with PV or processed in order to validate siRNA activity. Total RNA and protein
360 were collected and assessed by quantitative RT-PCR and western blot, respectively.

361 In order to evaluate the interaction of HLA-DR with H17 we used the HLA DRA mAb
362 (302CT2.3.2), which is generated from mice immunized with a KLH conjugated synthetic

peptide between 48-75 amino acids from human HLA-DRA. After a 1 h pre-incubation with increasing concentrations of the antibody in normal growth media, Raji cells (3×10^4) were infected for 24-48 h with H17-or VSV-G-PV.

Western blot analysis

Washed cells were lysed on ice with lysis buffer [0.5% NP40 in PBS with 10 mM Tris-HCl, pH 7.4 supplemented with Halt Protease Inhibitor mixture EDTA-free (Thermo Fisher Scientific UK)] and protein was quantified by the BCA assay kit (Thermo Fisher Scientific, UK). 20-50 μ g of protein was electrophoresed on a 4-15% sodium dodecylsulfate polyacrylamide gel, alongside a protein ladder (Precision Plus Protein Dual Colour Standards, Bio-Rad) and immunoblotted with the following antibodies using standard procedures: mouse monoclonal anti-HLA-DRA (1:1000; Clone: 302CT2, Enzo Life Sciences, UK) or rabbit monoclonal α -tubulin (1:2000; Cell signalling Technology, UK) antibodies. The membranes were then washed with PBS for three times and incubated with goat anti-rabbit or donkey anti-mouse secondary antibodies (LI-COR) in the dark for 1 h. Scanning was then carried out using the Odyssey Imaging system (LI-COR).

Immunofluorescence

Transfected cells with HLA-DRA and -DRB1 expression plasmids or with the empty plasmid were seeded onto glass cover slips at 5×10^4 cells/ml in 6 well plates overnight and were fixed with 4% paraformaldehyde in PBS for 30 minutes at room temperature (RT). Fixed cells were washed with PBS and permeabilised with 1% Triton X-100 in PBS for 10 minutes. After washing with PBS, the cover slips were incubated with a mouse HLA-DRA mAb (169-1B5.2; Bio-Techne Ltd) targeting a monomorphic general framework determinant of HLA-DR Class II antigen, diluted in 5% BSA/PBS for 1 hr at RT. The cover slips were then washed 3X with 0.02% Tween 20 and 1% BSA in PBS, followed by incubation with Alexafluor 488 conjugated

anti-mouse (Thermo Fisher Scientific, UK) for 30 minutes at RT. After washing 3X with 0.02% Tween 20 and 1% BSA in PBS, the cover slips were mounted using Prolong Gold containing DAPI (Invitrogen). Images were acquired on EVOS fluorescent microscope (EVOS FL imaging system; Life Technology, USA). Experiments were carried out twice.

Flow cytometry

For surface staining, human cancer cells and HEK293T/17 cells transfected with an empty vector or expression plasmids of HLA-DR (α and β) chains were maintained in the dark at 4°C throughout. Cells were collected, washed twice in ice-cold FACS buffer (2%FCS, 0.02% NaN₃ in PBS) and stained with a FITC-conjugated anti-human HLA-DR mAb (Clone Tü36; BD Biosciences). This antibody specifically binds to a monomorphic epitope of the HLA-DR $\alpha\beta$ complex and not the isolated α or β chains or the HLA-DP and -DQ isotypes⁴¹. The cells were analyzed with BD LSR Fortessa to determine expression of HLA-DR in combination with the matched isotype control and sorted into HLA-DR⁻ and HLA-DR⁺ subpopulations with a FACS Aria cell sorter (BDIS, San Jose, CA, USA). The Hoechst 33342 stain was used for cell viability discrimination and the data files were analyzed using the FlowJo software (Tree Star, Inc., Sacramento, CA, USA). Data are representative of two independent experiments.

Relative and absolute mRNA quantification

qRT-PCR was performed on RNA samples using a two-step procedure. RNA was first reverse-transcribed into cDNA using the QuantiTect Reverse Transcription Kit (Qiagen) according to manufacturer's instructions. qRT-PCR was then conducted on the cDNA in a 384-well plate with a ABI-7900HT Fast qRT-PCR system (Applied Biosystems). Mesa Green qRT-PCR MasterMix (Eurogentec) was added to the cDNA (5 μ l for every 2 μ l of cDNA). The following primers were used: for canine DLA-DRA (Forward: 5'-GCTGTGGACAAAGCTAACCTTG-3', Reverse: 5'-TCTGGAGGTACATTGGTGTTCG-3'), for canine DLA-DRB1 (Forward: 5'-

AGCACCAAGTTTGACAAGC-3', Reverse: 5-AAGAGCAGACCCAGGACAAAG-3'). The following amplification conditions were used: 95°C for 5 minutes; 40 cycles of 95°C for 15 seconds, 57°C for 20 seconds, and 72°C for 20 seconds; 95°C for 15 seconds; 60°C for 15 seconds; and 95°C for 15 seconds. The output Ct values and dissociation curves were analysed using SDS v2.3 and RQ Manager v1.2 (Applied Biosystems). Gene expression data were normalized against the housekeeping gene GAPDH, and compared with the mock controls using the comparative C_T method (also referred to as the 2^{-ΔΔCT} method⁵⁸). Absolute copy numbers of HLA-DRA in human cell lines were calculated using a standard curve of known concentrations of the corresponding HLA-DRA cDNA expression plasmid. HLA-DRA (Forward: 5'-TCAAGGGATTGCGCAAAGC-3' and reverse 5'-ACACCATCACCTCCATGTGC-3'. All experiments were carried out in triplicate.

Prediction of transmembrane protein domains and subcellular topology and phylogenetic analysis

For each of the differentially regulated transcripts identified by microarrays, we used Phobius (<http://phobius.sbc.su.se>)⁵⁹ and TMHMM v2.0 (<http://www.cbs.dtu.dk/services/TMHMM/>)⁶⁰ to predict the existence of transmembrane protein domains. Similarly, we used Deeploc-1.0 (<http://www.cbs.dtu.dk/services/DeepLoc/>)⁶¹ to determine sub-cellular localisation of the encoded proteins. These predictions were compared with gene annotations and literature references to confirm their reliability. The amino acid sequences of canine DLA-DRA (NP_001011723.1), human HLA-DRA (NP_061984.2), and their bat orthologues [*Pteropus alecto* (XP_006907484.1) and *Desmodus rotundus* (XP_024413747.1)] were subjected to multiple alignment using CLC workbench 7 (CLC Bio, Qiagen, Aarhus, Denmark).

Ethics statement

440 The buffy coat residues for the isolation of CD19⁺ primary B cells were purchased from the UK
441 Blood Transfusion Service from anonymous volunteers blood donors. Therefore, no ethical
442 approval is required.

443

444 **Statistical Analyses**

445 Graphical representation and statistical analyses were performed using Prism 8 software
446 (GraphPad). Unless otherwise stated, results are shown as means $\pm$ SEM from three
447 independent experiments. Differences were tested for statistical significance using one-way
448 ANOVA with a Dunnett's or a Tukey *posthoc* test. All statistical analyses were two-sided, and p
449 <0.05 was considered statistically significant.

450

451 **Acknowledgements:**

452 Our thanks go to Jim Kaufman, Yanping Guo, Rob White, Amr Bayoumy, Ibrahim Elbusifi,
453 Daragh Quinn and Alfred Ho for their technical assistance. This research was undertaken with
454 the financial support of the Biotechnology and Biological Sciences Research Council (BBSRC)
455 (<http://www.bbsrc.ac.uk>) via Strategic LoLa grant BB/K002465/1 "Developing Rapid
456 Responses to Emerging Virus Infections of Poultry (DRREVIP)" and the Octoberwoman
457 Foundation.

458

459 **References:**

- 460 1. Tong S, *et al.* A distinct lineage of influenza A virus from bats. *Proc Natl Acad Sci U S A*
461 **109**, 4269-4274 (2012).
- 462 2. Tong S, *et al.* New world bats harbor diverse influenza A viruses. *PLoS Pathog* **9**,
463 e1003657 (2013).
- 464 3. Kandeil A, *et al.* Isolation and characterization of a distinct influenza A virus from
465 Egyptian bats. *J Virol*, (2018).
- 466 4. Brunotte L, Beer M, Horie M, Schwemmle M. Chiropteran influenza viruses: flu from
467 bats or a relic from the past? *Curr Opin Virol* **16**, 114-119 (2016).
- 468
- 469
- 470

- 471
- 472 5. Simonsen L. The global impact of influenza on morbidity and mortality. *Vaccine* **17**
- 473 **Suppl 1**, S3-10 (1999).
- 474
- 475 6. Long JS, Mistry B, Haslam SM, Barclay WS. Host and viral determinants of influenza A
- 476 virus species specificity. *Nat Rev Microbiol*, (2018).
- 477
- 478 7. Gamblin SJ, Skehel JJ. Influenza hemagglutinin and neuraminidase membrane
- 479 glycoproteins. *J Biol Chem* **285**, 28403-28409 (2010).
- 480
- 481 8. Bertram S, Glowacka I, Steffen I, Kuhl A, Pohlmann S. Novel insights into proteolytic
- 482 cleavage of influenza virus hemagglutinin. *Rev Med Virol* **20**, 298-310 (2010).
- 483
- 484 9. Lakadamyali M, Rust MJ, Zhuang X. Endocytosis of influenza viruses. *Microbes Infect* **6**,
- 485 929-936 (2004).
- 486
- 487 10. Sauter NK, *et al.* Hemagglutinins from two influenza virus variants bind to sialic acid
- 488 derivatives with millimolar dissociation constants: a 500-MHz proton nuclear
- 489 magnetic resonance study. *Biochemistry* **28**, 8388-8396 (1989).
- 490
- 491 11. Edinger TO, Pohl MO, Stertz S. Entry of influenza A virus: host factors and antiviral
- 492 targets. *J Gen Virol* **95**, 263-277 (2014).
- 493
- 494 12. Harrison SC. Viral membrane fusion. *Nat Struct Mol Biol* **15**, 690-698 (2008).
- 495
- 496 13. Air GM, Laver WG. The neuraminidase of influenza virus. *Proteins* **6**, 341-356 (1989).
- 497
- 498 14. Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD. Neuraminidase is
- 499 important for the initiation of influenza virus infection in human airway epithelium. *J*
- 500 *Virol* **78**, 12665-12667 (2004).
- 501
- 502 15. Sun X, *et al.* Bat-derived influenza hemagglutinin H17 does not bind canonical avian or
- 503 human receptors and most likely uses a unique entry mechanism. *Cell Rep* **3**, 769-778
- 504 (2013).
- 505
- 506 16. Li Q, *et al.* Structural and functional characterization of neuraminidase-like molecule
- 507 N10 derived from bat influenza A virus. *Proc Natl Acad Sci U S A* **109**, 18897-18902
- 508 (2012).
- 509
- 510 17. Zhu X, *et al.* Crystal structures of two subtype N10 neuraminidase-like proteins from
- 511 bat influenza A viruses reveal a diverged putative active site. *Proc Natl Acad Sci U S A*
- 512 **109**, 18903-18908 (2012).
- 513
- 514 18. Wu Y, Wu Y, Tefsen B, Shi Y, Gao GF. Bat-derived influenza-like viruses H17N10 and
- 515 H18N11. *Trends Microbiol* **22**, 183-191 (2014).
- 516
- 517 19. Maruyama J, *et al.* Characterization of the glycoproteins of bat-derived influenza
- 518 viruses. *Virology* **488**, 43-50 (2016).
- 519
- 520 20. Garcia-Sastre A. The neuraminidase of bat influenza viruses is not a neuraminidase.
- 521 *Proc Natl Acad Sci U S A* **109**, 18635-18636 (2012).

522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572

21. Cimini K, Thamamongood T, Zimmer G, Schwemmle M. Novel insights into bat influenza A viruses. *J Gen Virol* **98**, 2393-2400 (2017).
22. Mehle A. Unusual influenza A viruses in bats. *Viruses* **6**, 3438-3449 (2014).
23. Juozapaitis M, *et al.* An infectious bat-derived chimeric influenza virus harbouring the entry machinery of an influenza A virus. *Nat Commun* **5**, 4448 (2014).
24. Hoffmann M, Kruger N, Zmora P, Wrensch F, Herrler G, Pohlmann S. The Hemagglutinin of Bat-... *PLoS One* **11**, e0152134 (2016).
25. Zhou B, *et al.* Characterization of uncultivable bat influenza virus using a replicative synthetic virus. *PLoS Pathog* **10**, e1004420 (2014).
26. Moreira EA, *et al.* Synthetically derived bat influenza A-like viruses reveal a cell type- but not species-specific tropism. *Proc Natl Acad Sci U S A* **113**, 12797-12802 (2016).
27. Carnell GW, Ferrara F, Grehan K, Thompson CP, Temperton NJ. Pseudotype-based neutralization assays for influenza: a systematic analysis. *Front Immunol* **6**, 161 (2015).
28. Li Q, Liu Q, Huang W, Li X, Wang Y. Current status on the development of pseudoviruses for enveloped viruses. *Rev Med Virol* **28**, (2018).
29. King B, Daly J. Pseudotypes: your flexible friends. *Future Microbiol* **9**, 135-137 (2014).
30. Coakley E, Petropoulos CJ, Whitcomb JM. Assessing chemokine co-receptor usage in HIV. *Curr Opin Infect Dis* **18**, 9-15 (2005).
31. Cronin J, Zhang XY, Reiser J. Altering the tropism of lentiviral vectors through pseudotyping. *Curr Gene Ther* **5**, 387-398 (2005).
32. Carnell G, *et al.* The bat influenza H17N10 can be neutralized by broadly- neutralizing monoclonal antibodies and its neuraminidase can facilitate viral egress. bioRxiv 499947; doi: <https://doi.org/10.1101/499947> (2018).
33. Dukes JD, Whitley P, Chalmers AD. The MDCK variety pack: choosing the right strain. *BMC Cell Biol* **12**, 43 (2011).
34. Nowak SA, Chou T. Mechanisms of receptor/coreceptor-mediated entry of enveloped viruses. *Biophys J* **96**, 2624-2636 (2009).
35. Byrd-Leotis L, Cummings RD, Steinhauer DA. The interplay between the host receptor and influenza virus hemagglutinin and neuraminidase. *Int J Mol Sci* **18**, (2017).
36. Kaufman JF, Auffray C, Korman AJ, Shackelford DA, Strominger J. The class II molecules of the human and murine major histocompatibility complex. *Cell* **36**, 1-13 (1984).
37. Blazekovic F, *et al.* HLA-DR peptide occupancy can be regulated with a wide variety of small molecules. *Hum Vaccin Immunother* **12**, 593-598 (2016).

- 573 38. Jones EY, Fugger L, Strominger JL, Siebold C. MHC class II proteins and disease: a
574 structural perspective. *Nat Rev Immunol* **6**, 271-282 (2006).
575
- 576 39. Roche PA, Furuta K. The ins and outs of MHC class II-mediated antigen processing and
577 presentation. *Nat Rev Immunol* **15**, 203-216 (2015).
578
- 579 40. Nagy ZA, *et al.* Fully human, HLA-DR-specific monoclonal antibodies efficiently induce
580 programmed death of malignant lymphoid cells. *Nat Med* **8**, 801-807 (2002).
581
- 582 41. Ziegler A, *et al.* Analysis by sequential immunoprecipitations of the specificities of the
583 monoclonal antibodies TU22, 34, 35, 36, 37, 39, 43, 58 and YD1/63. HLK directed
584 against human HLA class II antigens. *Immunobiology* **171**, 77-92 (1986).
585
- 586 42. Watanabe N, *et al.* A cell-based high-throughput screening assay system for inhibitor
587 compounds of antigen presentation by HLA class II molecule. *Sci Rep* **7**, 6798 (2017).
588
- 589 43. van Lith M, McEwen-Smith RM, Benham AM. HLA-DP, HLA-DQ, and HLA-DR have
590 different requirements for invariant chain and HLA-DM. *J Biol Chem* **285**, 40800-40808
591 (2010).
592
- 593 44. Grove J, Marsh M. The cell biology of receptor-mediated virus entry. *J Cell Biol* **195**,
594 1071-1082 (2011).
595
- 596 45. Stamatakis Z, *et al.* Hepatitis C virus association with peripheral blood B lymphocytes
597 potentiates viral infection of liver-derived hepatoma cells. *Blood* **113**, 585-593 (2009).
598
- 599 46. Lemon K, *et al.* Early target cells of measles virus after aerosol infection of non-human
600 primates. *PLoS Pathog* **7**, e1001263 (2011).
601
- 602 47. Shannon-Lowe CD, Neuhierl B, Baldwin G, Rickinson AB, Delecluse HJ. Resting B cells
603 as a transfer vehicle for Epstein-Barr virus infection of epithelial cells. *Proc Natl Acad*
604 *Sci U S A* **103**, 7065-7070 (2006).
605
- 606 48. Rensing ME, *et al.* Interference with T cell receptor-HLA-DR interactions by Epstein-
607 Barr virus gp42 results in reduced T helper cell recognition. *Proc Natl Acad Sci U S A*
608 **100**, 11583-11588 (2003).
609
- 610 49. Rensing ME, *et al.* Epstein-Barr virus gp42 is posttranslationally modified to produce
611 soluble gp42 that mediates HLA class II immune evasion. *J Virol* **79**, 841-852 (2005).
612
- 613 50. Wiertz EJ, Devlin R, Collins HL, Rensing ME. Herpesvirus interference with major
614 histocompatibility complex class II-restricted T-cell activation. *J Virol* **81**, 4389-4396
615 (2007).
616
- 617 51. Jeffers SA, *et al.* CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome
618 coronavirus. *Proc Natl Acad Sci U S A* **101**, 15748-15753 (2004).
619
- 620 52. Li W, *et al.* Angiotensin-converting enzyme 2 is a functional receptor for the SARS
621 coronavirus. *Nature* **426**, 450-454 (2003).
622

53. Ferrara F, *et al.* The human Transmembrane Protease Serine 2 is necessary for the production of Group 2 influenza A virus pseudotypes. *J Mol Genet Med* **7**, 309-314 (2012).
54. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. *Nat Biotechnol* **15**, 871-875 (1997).
55. Demaison C, *et al.* High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. *Hum Gene Ther* **13**, 803-813 (2002).
56. Cox RJ, Mykkeltvedt E, Robertson J, Haaheim LR. Non-lethal viral challenge of influenza haemagglutinin and nucleoprotein DNA vaccinated mice results in reduced viral replication. *Scand J Immunol* **55**, 14-23 (2002).
57. Giotis ES, Ross CS, Robey RC, Nohturfft A, Goodbourn S, Skinner MA. Constitutively elevated levels of SOCS1 suppress innate responses in DF-1 immortalised chicken fibroblast cells. *Sci Rep* **7**, 17485 (2017).
58. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. *Nucleic Acids Res* **29**, e45 (2001).
59. Kall L, Krogh A, Sonnhammer EL. Advantages of combined transmembrane topology and signal peptide prediction--the Phobius web server. *Nucleic Acids Res* **35**, W429-432 (2007).
60. Krogh A, Larsson B, von Heijne G, Sonnhammer EL. Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes. *J Mol Biol* **305**, 567-580 (2001).
61. Almagro Armenteros JJ, Sonderby CK, Sonderby SK, Nielsen H, Winther O. DeepLoc: prediction of protein subcellular localization using deep learning. *Bioinformatics* **33**, 4049 (2017).

Figure legends:

Figure 1: a. Schematic representation of pseudotype virus production. Expression plasmids for the HIV-1 gag-pol gene, the bat H17 alone or with N10, the luciferase reporter gene with HIV-1 long tandem repeats (LTRs) and the protease gene (HAT or TMPRSS2) are generated and co-transfected into producer HEK293T/17 cells. Cells transcribe and translate the HIV-1 core genes, BatIV glycoproteins are packaged on the cell surface, and viruses bud off in an HIV-1 dependent manner. Production of N10-PV does not require co-transfection with a

668 protease gene. Supernatants are harvested at 48 h post-transfection and the produced
669 pseudotype viruses (PVs) are filtered, titrated and infected into target cells. **b.** Infectivity
670 titers of H17-PV in cells from different tissues/species [expressed in Relative Luciferase Units
671 (RLU)/ml]. Mean luciferase activity was plotted as mean $\pm$ inter-assay deviation expressed as
672 SEM from 3-6 independent experiments. **c.** Infectivity titers of H17-PV, N10 and control
673 pseudotypes (VSV-G, H5 and Δ -env) in MDCK II cells. **d.** MDCK II cells were pre-treated with
674 either neuraminidase (2 h), with pronase (30 mins) or tunicamycin (5 h) or treated with
675 ammonium chloride, and then infected with H17-PV. Luciferase activities were measured
676 after 24 h with a luminometer. The left Y-axis shows infection levels (% of control) and the
677 right Y-axis shows % viability of cells related to control MDCK II cells. Experiments were
678 carried out in triplicate.

Figure 2: a. Significantly expressed genes in the microarray comparison of late versus early passaged MDCK cells (green and red columns represent upregulated transcripts in MDCK II and MDCK I cells respectively). Analysis was conducted with Partek (fold change ≥ 1.5 and FDR ≤ 0.05). Red frame indicates the transcript upregulated in late passaged MDCK cells encoding a membrane protein. **b.** qRT-PCR results showing the expression of DLA-DRA and DLA-DRB1 mRNA in MDCK I and II cells. The data are expressed as the means $\pm$ S.E.M. from three independent experiments. One-way Anova with Tukey *posthoc* test were used to analyse the data. $**P < 0.005$ versus control. **c.** Schematic diagram of the MHC II surface molecules. **d.** Left Y-axis (green box and whiskers): relative infection titers of H17-PV [$\log_{10}$ Relative Luciferase Units (RLU) /ml] in a panel of human cancer cell lines. Right Y-axis (broken purple line) shows $\log_{10}$ HLA-DRA mRNA copies with qRT-PCR. The data are expressed as the means $\pm$ S.E.M. from three independent experiments. **e.** FACS analysis of the expression levels of cell-surface HLA-DR molecule from three H17-PV susceptible and three unsusceptible cancer cell lines. Results are representative from two independent experiments. Blue and red peaks represent HLA-DR⁻ and HLA-DR⁺ subpopulations respectively. **f.** Left: infection titers of VSV-G- and H17-PV (RLU/ml) in Raji cells transfected with siControl or siHLA-DRA. Right: western blot (top) and qRT-PCR (bottom) showing expression of HLA-DRA protein and mRNA in transfected Raji with siRNA versus siControl. Experiments were carried out twice and the data are expressed as means $\pm$ S.E.M. One-way Anova with Dunnett *posthoc* test were used to analyse the data. $**P < 0.005$ versus siControl. **g.** Relative infection titers of VSV-G- and H17-PV (RLU/ml) in Raji cells incubated with different concentrations of a monoclonal antibody targeting HLA-DRA. The data are expressed as the means $\pm$ S.E.M. from three independent experiments. **h.** FACS analysis of the expression levels of cell-surface HLA-DR heterodimer in transiently transfected HEK293T/17 cells for 48 h with expression vectors for DRA and DRB1 (1:1 ratio). Right hand corner microscopy picture (80x) shows immunofluorescence confirming surface expression of HLA-DR on cells (green stain: FITC-HLA-DR and blue: DAPI).

708 The data are representative from two independent experiments. **i.** Relative infection titers of
 709 VSV-G- and H17-PV [in log₁₀ Relative Luciferase Units (RLU) /ml] in FACS-sorted DR-
 710 HEK293T/17 cells, unsorted transiently transfected (DR⁺ & DR⁻) and FACS-sorted DR⁺ cells.
 711 Experiments were carried out twice and the data are expressed as the means $\pm$ S.E.M. One-
 712 way Anova with Dunnett *posthoc* test were used to analyse the data. ***P*<0.005 versus DR-
 713 cells.

722 Supplementary material

723 Supplementary Material 1: List of cell lines included in the study.

Cell line	Type of cells	Species	Origin
Raji	Burkitt's lymphoma mature B-cells	Human	ATCC CCL-86
Ramos	Burkitt's lymphoma mature B-cells	Human	ATCC CRL-1596
BJAB	Burkitt's lymphoma mature B-cells	Human	CVCL_5711
HL-60	Promyeloblasts	Human	ATCC CCL-240
Molt-4	T lymphoblasts	Human	ATCC CRL-1582
Jurkat	T lymphocytes	Human	ATCC TIB-152
U-937	Monocytic leukemia	Human	ATCC CRL-1593.2
THP-1	Monocytic lymphoma	Human	ATCC TIB-202
B-LCLs	B-lymphoblastoid	Human	DOI: 10.1093/nar/gkw1167
Kasumi-1	Myeloblasts	Human	ATCC CRL-2724
Tb1 Lu	Epithelial lung	<i>Tadarida brasiliensis</i>	ATCC CCL-88
<i>S. lilium</i> lung	Lung	<i>Sturnira lilium</i>	Adolfo-Garcia Sastres & Martinez (The Icahn School of Medicine at Mount Sinai, NY, USA)/Aguilera's labs (Univ. of Costa Rica)
<i>S. lilium</i> kidney	Kidney	<i>Sturnira lilium</i>	
<i>Ar. literatus</i> lung	Lung	<i>Artibeus literatus</i>	
<i>C. perspic</i> kidney	Kidney	<i>Carollia perspicillata</i>	
<i>C. perspic</i> lung	Lung	<i>Carollia perspicillata</i>	
<i>C. perspic</i> liver	Liver	<i>Carollia perspicillata</i>	Linfa Wang lab, NUS DOI: 10.1371/journal.pone.000826
PakiT03 cells	Epithelial kidney	<i>Pteropus Alecto</i>	
PaBr cells	Brain	<i>Pteropus Alecto</i>	
A549 cells	Epithelial lung	Human	ATCC CRM-CCL-185
BEAS-2B	Epithelial lung/bronchus	Human	ATCC CRL-9609
HFF-1	Skin fibroblasts	Human	ATCC SCRC-1041
HeLa	Epithelial cervix	Human	ATCC CCL-2
HeLa S3	Epithelial cervix	Human	ATCC CCL-2.2
Caco-2	Epithelial colon	Human	ATCC HTB-37
HEK293T17	Kidney	Human	ATCC CRL-11268
DF-1	Embryo fibroblast	Chicken	ATCC CRL-12203
HD11	Macrophages	Chicken	CVCL_4685
CEF	Embryo fibroblasts	Chicken	The Pirbright Institute, UK
CER	Embryo-related	Chicken	DOI: 10.1016/j.biologicals.2005.08.001
Ou2	Fibroblasts	Chicken	CVCL_Y589
HD6	Erythroblasts	Chicken	PMCID: PMC230774

HP46	ALV-carcinoma	Chicken	PMCID: PMC361083
Cu447	Tumor cell line	Quail	DOI: 10.1637/7182-032604R
Cu453	Tumor cell line	Quail	DOI: 10.1637/7182-032604R
QT35	Muscle fibroblasts	Quail	ECACC:93120832
NMuMG	Mammary gland	Mouse	ATCC CRL-1636
LTK-11	Fibroblasts	Mouse	ATCC CRL-10422
BS-C-1	Kidney epithelial	Monkey	ATCC CCL 26
PK-15	Kidney epithelial	Pig	ATCC CCL-33
Wg3HCL2	HGPRT-Chinese hamster fibroblasts	Hamster	DOI: 10.1186/1297-9686-34-4-521
BHK-21	Kidney fibroblast	Hamster	ATCC CCL-10
CHO 1-15	Ovary epithelial	Hamster	ATCC CRL-9606
NBL-2	Epithelial kidney	Canine	ATCC CCL-34
MDCK I	Epithelial kidney	Canine	EEACC 00062106
MDCK II	Epithelial kidney	Canine	EEACC 00062107

Supplementary Material 2: List of the differentially regulated genes determined by microarray comparison between early and late passaged MDCK cells, as summarised in Fig. 2a. The encoded proteins of the differentially regulated transcripts were surveyed for their subcellular localisation (with the DeepLoc server) and presence of transmembrane domains (using the PHOBIUS and TMHMM algorithms).

Affymetrix ID	Refseq ID	Gene symbol	Gene name	Subcellular localisation (DeepLoc server)	Predicted transmembrane domains		FDR	Fold change
					TMHMM server	Phobius server		
Cfa.12195.3.S1_at	XM_003435535 XM_005641862 XM_014111636 XM_861215	FHL1	Four and a half LIM domains 1	Nucleus, Soluble	0		2.63E-05	8.68212
CfaAffx.10229.1.S1_at	NM_001159684	CYP1B1	Cytochrome P450, family 1, subfamily B, polypeptide 1	Endoplasmic reticulum, Membrane	0		1.28E-05	4.30944
Cfa.10821.1.A1_s_at	XM_005637210 XM_848227	C1S	Complement component 1, s subcomponent	Extracellular, Soluble	0		4.36E-06	4.21145

Cfa.12556.1.A1_at	XM_014119919	NUB1	Negative regulator of ubiquitin-like proteins 1	Cytoplasm, Soluble	0		2.01E-05	4.14298
Cfa.4394.1.S1_at	XM_014111110	SERPINE2	Serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1)	Extracellular, Soluble	0		2.01E-05	3.70338
Cfa.7284.1.A1_s_at	XM_014119919	NUB1	Negative regulator of ubiquitin-like proteins 1	Cytoplasm, Soluble	0		2.21E-05	3.22491
Cfa.6456.1.S1_at	NM_001011723 XM_005627066 XM_005627067	DLA-DRA	MHC class II DR alpha chain	Cell membrane, Membrane	1	221-241	2.77E-05	3.21344
Cfa.127.1.S1_s_at	NM_001194952	PLAU	Plasminogen activator, urokinase	Extracellular, Soluble	0	20-40	2.14E-05	2.69368
CfaAffx.6163.1.S1_at	XM_532876	PDIA6	Protein disulfide isomerase family A, member 6	Endoplasmic reticulum, Soluble	0		1.83E-05	2.10444
Cfa.4275.2.S1_at	XM_843145	PDIA4	Protein disulfide isomerase family A, member 4	Endoplasmic reticulum, Soluble	1		8.19E-06	2.05558

CfaAffx.6163.1.S1_s_at	XM_532876	PDIA6	Protein disulfide isomerase family A, member 6	Endoplasmic reticulum, Soluble	0		8.36E-06	1.9391
CfaAffx.26500.1.S1_s_at	XM_014116111 XM_537530	SEL1L	Sel-1 suppressor of lin-12-like (C. elegans)	Endoplasmic reticulum, Membrane	1	768-786	5.15E-06	1.69924
Cfa.12560.1.A1_at	XM_005636642 XM_014108134 XM_847958 XR_001314613 XR_001314614	RNLS	Renalase, FAD-dependent amine oxidase	Mitochondrion, Membrane	0		3.65E-07	- 1.64221
CfaAffx.22914.1.S1_at	NM_001287170	BMP4	Bone morphogenetic protein 4	Nucleus, Soluble	0		2.56E-05	- 1.93435
Cfa.64.1.S1_at	NM_001003025	ID3	Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein	Nucleus, Soluble	0		3.38E-06	- 3.17884
Cfa.825.1.S2_at	NM_001003308	SLC2A3	Solute carrier family 2 (facilitated glucose transporter), member 3	Cell membrane, Membrane	10	7-26, 62-85, 97-115, 121-142, 154-177, 183-205, 270-293, 305-326, 333-355, 361-379, 400-420, 426-448	6.71E-06	- 5.03551

						7-26, 62-85, 97-115, 121- 142, 154- 177, 183- 205, 270- 293, 305- 326, 333- 355, 361- 379, 400- 420, 426-448		
CfaAffx.21479.1.S1_at	NM_001003308	SLC2A3	Solute carrier family 2 (facilitated glucose transporter), member 3	Cell membrane, Membrane	10	2.21E- 05	- 5.89883	

731
732

733 **Supplementary Material 3: The ectodomain of HLA-DRA is well conserved in bats,**
734 **humans and canine.**

735 Multiple amino acid sequence alignment of canine DLA-DRA (NP_001011723.1), human HLA-
736 DRA (NP_061984.2), and their bat orthologues [(Yinpterochiroptera *Pteropus alecto*
737 (XP_006907484.1) and Yangochiroptera *Desmodus rotundus* (XP_024413747.1)]. *Desmodus*
738 *rotundus* (common vampire bat) was chosen as the closest species to *Sturnira lilium* with a
739 decoded genome. The alignment was performed by importing the corresponding amino acid
740 sequences into CLC Workbench (CLC Bio, Qiagen, Aarhus, Denmark). Orange arrows indicate
741 the ectodomain of the protein. Matrix below shows overall, pairwise amino acid similarity of
742 HLA-DRA between the four species. The percent amino acid similarity values were calculated
743 with the CLC workbench program.

	1	2	3	4
Canis lupus familiaris	1	89.01	88.48	89.53
Homo sapiens	2	89.01	86.39	87.96
Desmodus rotundus	3	88.48	86.39	89.01
Pteropus alecto	4	89.53	87.96	89.01

Supplementary Material 4: Transfection of HEK293T/17 with HLA-DR α and β chains results in surface expression of the heterodimer.

HEK293T/17 cells were transfected with the empty vector or with HLA-DRA and DRB1 expression plasmids. The cells were fixed in paraformaldehyde and were permeabilised with Triton X-100 to show intracellular distribution and immuno-stained with mAb HLA-DRA. Nuclei were stained blue with DAPI stain (left panel), HLA-DR heterodimers were stained green (middle panel), and the right panel shows a merged image. Fluorescent microscopy analysis was performed with the EVOS FL fluorescent imaging system. Original magnification, $\times 20$.

754

755 **Supplementary Material 5: Transfection of bat PakiTO3 cells with HLA-DR α and β**
 756 **chains confers susceptibility to H17-PV.**

757 Infectivity titers of H17-PV (RLU/ml) in PakiTO3 cells transfected for 48 h with equimolar
 758 amounts of either empty vector (pcDNA3.1) or the expression plasmid for HLA-DRA or the
 759 expression plasmids encoding both chains of HLA-DR. Cells were infected with PV for an extra
 760 72 h in the presence of neomycin. Data represent mean values $\pm$ SEM of three independent
 761 experiments. One-way Anova with Dunnett *posthoc* test were used to analyse the data.
 762 **** $P < 0.00005$ versus cells transfected with the empty vector.